Research progress on small molecule inhibitors of coronaviruses
10.12206/j.issn.1006-0111.202005020
- VernacularTitle:冠状病毒小分子抑制剂研究进展
- Author:
Zhengguang YAO
1
;
Zhibin WANG
2
;
Chunnian XIA
3
;
Chunlin ZHUANG
2
Author Information
1. School of Pharmacy, Zhejiang University of Technology, Hangzhou 310014, China;School of Pharmacy, Naval Medical University, Shanghai 200433, China.
2. School of Pharmacy, Naval Medical University, Shanghai 200433, China.
3. School of Pharmacy, Zhejiang University of Technology, Hangzhou 310014, China.
- Keywords:
coronavirus;
SARS-CoV;
MERS-CoV;
SARS-CoV-2;
targets;
inhibitors
- From:
Journal of Pharmaceutical Practice
2020;38(5):385-397
- CountryChina
- Language:Chinese
-
Abstract:
Coronavirus infection seriously threatens human health. There is no specific medication or vaccine so far. In recent years, domestic and foreign researchers have developed a variety of small-molecule inhibitors against the ligand S protein, RdRp, PLpro and 3CLpro of three highly pathogenic coronavirus, SARS-CoV，MERS-CoV，SARS-CoV-2. This article reviews the characteristics of these coronaviruses, action targets, small molecule inhibitors, and structure-activity relationships.
